Deborah Davis, Non-Executive Chair

Deborah has extensive global experience in platform business models, software, fintech, telecoms and e-commerce businesses.

After completing her undergraduate studies in Australia, Deborah spent 25 years in CEO and executive roles including 14 years in European and global senior leadership roles at internet platform businesses PayPal and eBay, and technology companies Symantec and Verizon.

She currently holds a number of Non-Executive Director and Board committee positions, including International Personal Finance plc, IDEX Biometrics ASA, Norway, The Institute of Directors UK and Which? Ltd (until 31/12/20). Her previous Board experience also includes private equity based ieDigital. Deborah is a trustee of the Southern African Conservation Trust.

Deborah is a Chartered Director and a Fellow of the Institute of Directors. She holds a Bachelor of Applied Science (Electronics) Honours degree from the University of Melbourne and a Sloan Masters in Science (Management) with Distinction from London Business School.

Peter Keeling, Chief Executive Officer

Peter has over 33 years’ experience as a leader, entrepreneur and strategist in the pharmaceutical industry. He has led international companies and teams with a focus on novel business models and product launches, including therapies, diagnostics and FMCG products.

Peter started his career as Distribution Manager at American Monitor Corporation where he oversaw the distribution of diagnostic reagents and equipment globally. He subsequently spent 11 years leading projects in both operational and strategic roles at the therapy division of the Wellcome Foundation, including Sales Manager for the pharmaceutical business in North and West Africa (four years), Commercial Director for a joint venture with Wellcome Indonesia (three and a half years) and Brand Director globally for Wellcome’s antiviral franchise (three and a half years). Wellcome was merged into Glaxo in 2004. Subsequently, he was Founder and Chief Executive Officer of Diagnology Inc, a US/Irish based venture backed diagnostics company which specialised in development and commercialisation of tests for sexually transmitted diseases (seven years). Peter founded and has led Diaceutics from its inception in 2005 to become a leader in precision testing commercialisation which currently supports the go to market biomarker programmes for the world’s largest pharmaceutical companies.

Peter holds a degree in business administration from Queens University Belfast, a Masters degree in European Marketing from Buckingham University Business School and spent an academic year as a Visiting Fellow at MIT’s Sloan business school in 1994 where he led a multi-corporation US think tank designed to look at the disruptive models in future patient health for the pharma industry. Peter has published several peer reviewed papers on precision medicine and is a respected speaker at precision medicine events around the world.

Ryan Keeling, Chief Innovation Officer

Ryan is an expert in the commercialisation of diagnostics and associated technology, with over 10 years’ experience in the field.

Ryan has led the development and commercialisation of the Group’s technology, including its proprietary data lake. Ryan has played a pivotal role in the Group’s technological and strategic development, previously acting as its Chief Operating Officer until June 2018. As CIO, Ryan is responsible for driving the Group’s product innovation, with a near term focus on the development of DXRX. Prior to joining Diaceutics in 2009, Ryan spent eight years as a software engineer for Aepona Limited, providing network infrastructure and related services to telecommunications operators.

Ryan holds a software engineering degree from Queens University, Belfast. Ryan is seen as a thought leader in the field of diagnostic commercialisation and data integration speaking at precision medicine and healthcare data conferences globally.

Nick Roberts FCA, Chief Financial Officer

As Chief Financial Officer, Nick is accountable for the financial health of the organisation, working alongside the EXCO team to determine overall direction for the company. He is responsible for developing, implementing and driving strategic plans collaborating across multiple functions, supporting the Board and leading investor reporting. Nick is an experienced senior finance professional with over 12 years’ experiences within the financial arena. He brings many years’ experience working with high growth AIM listed companies most recently in the pharmaceutical and green energy sector and has a proven record in managing growth companies with a strong platform focus.

Charles Hindson, Non-Executive Director

Charles joined the board as a Non-Executive director on IPO and chairs the audit and remuneration committees. He brings 16 years’ experience of FTSE listed company board membership, having served in executive director roles with Filtronic plc, first as Group Finance Director and subsequently Chief Executive, and then with e2v technologies plc, as Group Finance Director.

He is experienced in supporting business leaders develop technology businesses internationally, through organic growth and successful acquisitions, and this has been reflected in creating meaningful shareholder value with these listed companies.

 His early career was with 3i and PwC, and then in HQ and international divisional finance roles with British Gas plc and British Telecom plc before becoming Finance Director with Eutelsat SA, based in Paris, France. He also serves as a trustee and chair of the audit committee of Trinity College London, the international exam board for performing arts and English language qualifications, and is a member of its audit committee. He is also a trustee of UCO, a specialist higher education provider in osteopathy.

Michael Wort, Non-Executive Director

Having trained as a microbiologist, Mike brings over 40 years’ experience working with life science companies across the healthcare sector. Initially working with three of the top ten global pharmaceutical companies in a variety of sales, marketing and research positions, he was appointed Investor Relations Manager of Wellcome Plc and was actively involved in the global communications programme for the major £2.4 billion secondary offering of Wellcome Plc shares by the Wellcome Trust, which enabled him to develop working relationships with key figures in the life sciences industry.

After leaving Wellcome, Mike was a founding partner in the first specialist communications agency in the UK, for the emerging biotechnology industry. Apart from a diversion caused by his involvement as the CEO during the privatisation of the Bulgarian pharmaceutical industry his career has been devoted to working with start-up and growing SMEs to maximise their potential for growth.